Research company Chosa Oncology reports, as planned, no revenue and small changes in its result in the first quarter. The company reports a result after financial items of SEK -1.9 million (-1.8). Operating profit amounted to SEK -2.0 million (-1.5). During the quarter, Chosa Oncology carried out a directed issue of approximately SEK 7.3 million before issue costs. Cash and cash equivalents amounted at the end of the period to SEK 5.6 million (3.4). The company highlights new positive data from the phase III study SPLENDOUR in advanced lung cancer, presented at the European Lung Cancer Congress 2026. According to the company, the results showed that Platin-DRP could predict survival benefit from both carboplatin and cisplatin. CEO Peter Buhl Jensen says that the quarter marked the beginning of what the company assesses could become a transformative year for Chosa Oncology and that the new survival data strengthen the conviction that Platin-DRP can become an important decision support in clinical practice. "In summary, Q1 2026 was characterized by disciplined execution, strategic progress and growing scientific momentum. We are focused on continuing to develop CHOSAtoward our vision of improving precision within one of cancer care’s most important treatment areas", says the Chosa Oncology chief. Chosa Oncology, SEK millionQ1 2026Q1 2025ChangeOperating profit-2.0-1.5-29%Profit before tax-1.9-1.8-3%Net profit-1.9-1.8-3%Earnings per share, SEK-0.021-0.02516%